Objective To investigate the short-and long-term efficacy and safety of infliximab (IFX) in intestinal Behçet's disease (BD) patients in a retrospective cohort study. Methods Among 43 consecutive patients with intestinal BD presenting at the same clinic, 15 with active disease and receiving standard treatment were given IFX infusions (5 mg/kg body weight) every eight weeks. The patients were clinically and endoscopically evaluated before treatment, then assessed after 10 weeks, 12 months and 24 months for a clinical response, defined as a significant improvement in intestinal symptoms and a reduced C-reactive protein (CRP) level. Results At week 10, 12 patients (80%) exhibited a response to IFX, with eight (53%) in remission with no intestinal symptoms and normal CRP levels. A response to IFX was maintained in seven of the 11 patients (64%) available at 12 months and in four of the eight patients (50%) available at 24 months. Of the seven patients receiving prednisolone at entry, five responders had their steroid doses reduced. Fulminant intestinal BD was predictive of an absence of response to IFX. The adverse effects comprised one infusion reaction and one case of fever, most likely related to IFX. Conclusion IFX is effective and safe in patients with refractory intestinal BD.
Introduction
Behçet's disease (BD) is a chronic relapsing-remitting inflammatory immune disorder with diverse clinical manifestations, including orogenital aphthae and ocular, vascular, central nervous system, articular, mucocutaneous and gastrointestinal (GI) involvement (1, 2) . The condition was initially described in 1937 by Hulusi Behçet, a dermatologist practicing in Istanbul. BD is prevalent and a major cause of morbidity in countries along the ancient Silk Road and Mediterranean basin; however, it is uncommon in Western countries (1) .
Intestinal BD is a subtype characterized by intestinal le-sions and associated GI symptoms (2) . The condition has serious comorbidities, including GI bleeding and perforation, that are major factors in the poor response observed to conventional medications. Although corticosteroids (CSs) and immunomodulators have shown efficacy in cases of intestinal BD, many patients become refractory to these drugs and some patients are intolerant to particular drugs, such as aminosalicylates, mesalazine, CSs, azathioprine (AZA) and colchicine, that are commonly used to treat BD. Surgery is an option when the condition becomes fulminant; however, BD can recur and a patient may require surgery on more than one occasion (3, 4) . Therefore, new approaches to treatment with long-term efficacy and good safety profiles are required for better therapeutic outcomes in this disease.
Infliximab (IFX), a monoclonal antibody to tumor necrosis factor (TNF)-α, has been shown to be effective in patients with inflammatory bowel disease (IBD), thus inducing and maintaining remission in both Crohn's disease (CD) and ulcerative colitis (UC) (5) . This also demonstrates that inflammatory cytokines, notably TNF-α, play a major role in the immunopathogenesis of IBD (6) . Several case studies have also shown that IFX is effective in treating intestinal BD (7) (8) (9) (10) (11) (12) (13) . However, it is difficult to conduct prospective studies of patients with intestinal BD due to the rarity and heterogeneity of the disease. Therefore, we retrospectively evaluated the treatment outcomes of 15 patients with active intestinal BD who were refractory to conventional drugs and treated with IFX at a single center in Japan.
Materials and Methods

Patients
This retrospective cohort study followed 43 consecutive patients with intestinal BD who were regularly examined at the Inflammatory Bowel Disease Centre, Yokohama City University Medical Centre, between July 2005 and October 2011. The study protocol was approved by the Ethics Committee at Yokohama City University Medical Centre, and written informed consent was obtained from each patient. Systemic and intestinal BD were diagnosed using the criteria recommended by the Behçet's Disease Research Committee of Japan (2) . The intestinal BD activity was determined using the disease activity index for intestinal BD (DAIBD) (14) .
Criteria for IFX therapy
The following criteria were used at our center to identify intestinal BD patients who should receive IFX therapy: fulminant intestinal BD patients who presented with severe abdominal discomfort or extensive GI bleeding and required immediate and effective medication to prevent emergency surgery; refractory intestinal BD patients with active intestinal lesions (as shown on colonoscopy) despite receiving intensive treatment with one or a combination of prednisolone, colchicine, mesalazine or AZA for ! 8 weeks; steroiddependent patients who had responded to CS but in whom symptoms recurred when the dose was tapered; and patients with contraindications for or intolerance to CS. At our center, AZA was initiated at a low dose (0.5 to 1.5 mg/kg, estimated lean body weight daily) and increased incrementally to a maximum dose of 2.5 mg/kg daily, provided that the patient was tolerating the therapy and the white blood cell count was >4×10 3 /L.
IFX was administered at a dose of 5 mg/kg at 0, 2 and 6 weeks and then every eight weeks as maintenance therapy. As a general rule, the CS dose was tapered by 5-10 mg/day every two to four weeks in patients receiving prednisolone at the start of IFX therapy. In patients who relapsed when the dose of CS was tapered, with recurrence of abdominal symptoms and elevation of the C-reactive protein (CRP) level, the interval between IFX treatments was shortened from eight to four weeks.
Assessment of the short-and long-term efficacy of IFX
We were interested in the short-and long-term efficacy and safety of IFX in patients with intestinal BD refractory to conventional medications. The patients' clinical responses were assessed at 10 weeks (for short-term efficacy) and then at 12 and 24 months (for long-term efficacy) after the initiation of IFX therapy. We collected detailed patient histories, including demographic variables, laboratory data, history of abdominal surgeries related to intestinal BD, GI symptoms at the initiation of IFX therapy, systemic BD symptoms during the follow-up period and medications used for BD prior to or concomitant with IFX therapy. We also assessed the steroid-sparing effects of IFX.
Clinical remission was defined as the complete disappearance of GI symptoms, including abdominal discomfort, GI bleeding and diarrhea, accompanied by normalization of the serum CRP level. A clinical response was defined as a significant improvement in GI symptoms accompanied by a lower CRP level. Clinical relapse was defined as the exacerbation of GI symptoms accompanied by serum CRP elevation or confirmation of relapse of GI lesions on imaging studies that required intensification of treatment. The cumulative probability of treatment failure was calculated based on the interval between the initiation of IFX therapy and the time of GI symptom recurrence. Similarly, the cumulative probability of requiring surgery during IFX therapy was calculated based on the interval between the initiation of IFX therapy and the first surgery.
Colonoscopic evaluation of intestinal BD
Colonoscopy was performed before the initiation of IFX therapy in all patients in order to confirm the presence of active intestinal BD lesions. The colonoscopic evaluations were repeated at appropriate time points after the initiation of IFX administration. The intestinal lesions were categorized as "typical" or "atypical" as follows: deep, large, ovalshaped ulcers located in the ileocecal area were defined as typical lesions (2) ( Fig. 1, 2) ; lesions that did not fulfill these characteristics were defined as atypical. Additionally, in patients with a history of previous surgery, ulcers that recurred at ileocolic anastomoses were referred to as anastomotic. The maximum size of the lesions was also determined.
Statistical analysis
The data are presented as the mean ± standard deviation (SD), unless otherwise indicated. To determine the factors predictive of the response to IFX therapy, we used the chi squared test for nominal variables and the t-test for continuous variables. p<0.05 was considered to be statistically significant. C. Before IFX infusion D. One year after first IFX infusion B. One week after first IFX infusion A. Before IFX infusion
Results
Clinical data at baseline
Of the 43 consecutive patients with intestinal BD who visited our IBD center with related complications, 15 (seven men and eight women) were found to be eligible for inclusion in this study. None of these 15 patients had responded to conventional medications. Their baseline clinical features are shown in Table 1 . Their average age was 32 years at the diagnosis of BD and 39 years at the diagnosis of intestinal BD. Their average age was 45 years at the initiation of IFX therapy, and the average time from the onset of intestinal BD to the administration of IFX was 7 years, with a range of 2-21 years. Two patients had "complete type" BD, 11 (73%) had "incomplete type" BD and two had suspected BD. At the time of the first IFX infusion, 10 patients were suffering from abdominal discomfort, six had GI bleeding and eight had diarrhea. Five patients (33%) had a history of abdominal surgery for intestinal BD before the initiation of IFX therapy.
The colonoscopic findings at entry are summarized in Table 2, and typical examples of the intestinal BD lesions are shown in Figure 1 and 2. Colonoscopy showed characteristic intestinal BD lesions in eight patients and anastomotic ulcers in three patients. The remaining four patients were classified as having atypical intestinal lesions, including multiple aphthoid lesions, irregularly shaped ulcers or diffuse mucosal reddening. Four patients (27%) were treated for fulminant intestinal BD, 10 (66%) patients were treated for refractory intestinal BD and one patient received so-called "top-down" therapy with IFX owing to depression and contraindication of CS by his psychiatrist. Prior to the initiation of IFX therapy, nine (60%) patients had been treated with prednisolone, 13 (87%) patients had been treated with col- A. Before treatment B. Perforation at the ileocolic anastomosis (after resection). When appropriate, data are presented as the mean ± SD values.*p < 0.05; 5ASA: 5-aminosalycilic acid, 6MP: 6-mercaptopurine, AZA: azathioprine, CS: corticosteroid, DAIBD: disease activity index for intestinal Behçet's disease (values may vary from 325 -0, > 20: active disease), SD: standard deviation chicine, 14 (93%) patients had been treated with mesalazine and five (33%) patients had been treated with AZA.
Short-and long-term efficacy of IFX therapy
As shown in Table 3 , the evaluation of the efficacy of IFX therapy after 10 weeks showed a short-term response in 12 (80%) of the 15 treated patients. Clinical remission was achieved in eight (53%) patients, and a clinical response was observed in four (27%) patients. The three nonresponders were among the four patients who entered the study with fulminant intestinal BD. Two of these nonresponders required surgical intervention (Fig. 2) , and one achieved remission after being placed on high-dose CS therapy.
The efficacy of IFX therapy after 12 months was evaluated in 11 patients, seven (64%) of whom remained responders. Clinical remission was maintained in three (27%) (Fig. 1C, D) , and a clinical response continued to be observed in four (36%) patients. Among the patients who had been in clinical remission after 10 weeks, intestinal symptoms recurred in two patients; however, both of these patients continued to show a clinical response. The DAIBD scores significantly decreased following IFX therapy (Fig. 3) . The efficacy of IFX therapy at 24 months was evaluated in eight patients who were still available for an evaluation. Four (50%) of these patients remained responders, with three (38%) still in clinical remission and one continuing to show a clinical response. Of the seven patients who had demonstrated a response to IFX at 12 months, symptoms recurred in two patients when the CS dose was reduced, and both patients required surgery. Patient 1 received a single infusion of IFX due to his strong desire for a single dose and remained in remission for more than four years. In case 4, the frequency of IFX infusion was increased to four weeks, which allowed the CS dose to be reduced, and clinical remission without the administration of CS was maintained for more than two years. In fact, CS dose reduction was possible in five of the seven responders who were receiving prednisolone when the IFX therapy was initiated (Fig. 4) .
Follow-up colonoscopy was performed in all patients, except the two nonresponders who required emergency surgery. In four patients, the intestinal mucosa had healed completely, no BD lesions were present and complete remission was achieved. Partial improvements were observed in another four patients, while the remaining patients showed no improvements in intestinal morphology on colonoscopy.
The median follow-up period after the initiation of IFX therapy was 100 weeks, with a range of 16-341 weeks. The cumulative probability of recurrence at 10 weeks, 12 months and 24 months after the initiation of IFX therapy was 20%, Week 0 Week 10 12 months Prednisolone (mg/day) Mean ± SEM, n=7
29% and 51%, respectively (Fig. 5A) . The cumulative probability of requiring surgery during IFX therapy was 13% after one year and 37% after two years (Fig. 5B) .
Factors predictive of a clinical response to IFX
To identify factors predictive of a good clinical response to IFX, we compared the baseline clinical features and characteristics of the intestinal lesions in the responders and nonresponders using the chi squared test. The significant predictors of a failure to respond to IFX at 10 weeks included fulminant intestinal BD (p=0.001), a high DAIBD score (p=0.013), GI bleeding (p=0.02) and fever (p=0.024), which were not found to be independent factors (Table 1) , and endoscopic activity localized at anastomoses (p=0.02; Table 2 ). The duration of intestinal BD and the concomitant use of AZA were not significantly related to the clinical response to IFX in our analyses (Table 1) .
Safety
The only adverse side effects observed in the current study were an infusion reaction in one patient and fever thought to be related to IFX in another patient. No symptoms of BD occurred in organs other than the GI tract in any patient during our observation period.
Discussion
The present study showed that IFX is effective and safe in patients with refractory intestinal BD. No standard medical treatment for intestinal BD has been widely accepted, largely due to the rarity of the disease. Although CSs are effective and often used as the first-line drugs of choice (15) , they are associated with several serious adverse effects, and reducing the dose of CS often results in recurrence of symptoms. AZA, thalidomide and methotrexate have been reported to be effective for intestinal BD (4, 13, 15, 16) ; however, these immunosuppressants are not always efficacious. Anti-TNFα agents may be a new option for treating intestinal BD. There is now sufficient evidence in the literature to suggest that TNF blockade provides an important therapeutic advance in the treatment of severe ocular lesions in BD patients (17) . Although the pathobiology of BD remains largely unknown, recent genome-wide association studies have linked the condition with two genetic loci, IL23R-IL12 RB2 and IL-10, which are also associated with CD. This indicates that BD and CD may share a common underlying immunological disorder (18, 19) .
When we analyzed the efficacy of IFX therapy and the factors predictive of a clinical response in 15 patients with fulminant or refractory intestinal BD, IFX therapy was found to be effective in the short-term for the patients with intestinal BD, including those with long-standing disease, large ulcers or lesions in the ileum. IFX treatment was also effective in maintaining remission in some patients.
As the clinical course of some cases of intestinal BD differs from that of CD, the optimal regimen of IFX may differ between the two diseases. For example, patient 1 received a single infusion of IFX and remained in remission for more than four years. In some intestinal BD patients, the disease course is indolent (14) , and discontinuing IFX therapy is an option.
As is the case with CD, the loss of response to IFX is an important issue in patients with intestinal BD. After two years on 8-week IFX infusions, patient 4's symptoms recurred and CS treatment was required. Shortening the interval between infusions to four weeks allowed the CS dose to be reduced again, and a CS-free clinical remission continued for another two years. In addition to shortening the interval, the concomitant use of immunomodulators is another measure for preventing a loss of response, as Iwata and colleagues reported the efficacy of combination therapy with IFX and methotrexate (13) . Although the concomitant use of AZA was not significantly related to the short-term efficacy of IFX in our analysis, this finding does not contravene the efficacy of AZA administered in combination with IFX in the long term.
We found that failure to respond to IFX was strongly correlated with the clinical characteristics of severe disease, such as fulminant disease, high severity scores for intestinal BD, massive bleeding or fever at presentation and active ulcers at intestinal anastomoses. As IFX has been reported to be effective in CD patients with acute GI bleeding (20, 21) , we used it in three patients with fulminant intestinal BD and massive GI bleeding in the hope of achieving an immediate hemostatic effect. However, two of these patients required surgery and the third needed high-dose CS. It is important to consider intestinal BD patients with fulminant disease as possible candidates for surgical treatment. Naganuma and colleagues reported that BD patients showing ileal involvement tend to be more refractory to IFX therapy and more likely to require surgery than those with involvement of the cecum (12) . Recently, it has been reported that CD patients with a disease duration of <2 years are most likely to benefit from treatment with TNF antagonists (22) . In our analysis of 15 patients, a clinical response to IFX was not related to either the localization of the intestinal lesions or the duration of the disease. Further studies involving a larger number of patients are needed to clarify the prognostic factors of IFX therapy.
The only adverse events leading to cessation of IFX therapy in the current study were an infusion reaction in one patient and drug-induced fever in another patient. The treatment of BD is dictated by the organ system involved, and the treatment used for the disease affecting one specific organ can lead to the involvement of other organs in patients with BD. For example, cyclosporin A has been reported to promote the development of neurological manifestations of BD (23) . In this study, only GI symptoms were observed, and involvement of other organs did not develop during the course of IFX therapy.
In conclusion, the current study demonstrated acceptable efficacy and safety for IFX therapy in BD patients refractory to conventional treatments. This outcome validates the role of TNF-α in the immunopathogenesis of BD. However, if patients have fulminant disease or severe intestinal lesions refractory to IFX, performing resection may be necessary. Additional studies of larger cohorts of patients are needed to clarify the rationale underlying the outcomes observed in this investigation.
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